Immunosuppression related to hematological diseases
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: NGS Group: 1. Diagnosed with hematologic diseases (such as leukemia, lymphoma, multiple myeloma, etc.) accompanied by immunosuppression (due to the disease or its treatment) during the period from January 1, 2015, to June 30, 2025; 2. Clinically diagnosed with a suspected or confirmed infectious disease; 3. Submitted samples for pathogen metagenomic (mNGS) testing during the course of infection diagnosis and treatment. Control Group: 1.Diagnosed with hematologic diseases accompanied by immunosuppression during the same period; 2.Clinically diagnosed with a suspected or confirmed infectious disease; 3. Did not undergo mNGS testing, with pathogen detection conducted only using traditional microbiological methods.
Exclusion criteria
Exclusion criteria: 1.Clinical data are severely missing, making it impossible to evaluate efficacy or safety; 2. In this infection event, the mNGS was submitted more than 72 hours after the initial adjustment of anti-infective treatment (aiming to analyze the impact of mNGS on decision-making); 3. Patients who were discharged or died within 48 hours after submitting specimens for mNGS or conventional testing (unable to observe the intervention effect); 4.Patients who voluntarily abandoned treatment or were discharged.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30-day all-cause mortality;Etiological diagnostic efficacy (including overall detection rate, mixed infection detection rate, and testing turnaround time);The effective rate of infectious disease treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Initial treatment effective rate;Optimization of treatment decisions;The mortality rate related to this infection;90-day all-cause mortality;Consumption of medical resources; | — |
Countries
China
Contacts
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology